Journal of hematology and oncology, 2020-10, Vol.13 (1), p.144-144, Article 144
2020
Details
- Autor(en) / Beteiligte
- Titel
- Novel therapies are changing treatment paradigms in metastatic prostate cancer
- Ist Teil von
- Journal of hematology and oncology, 2020-10, Vol.13 (1), p.144-144, Article 144
- Ort / Verlag
- England: BioMed Central Ltd
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1756-8722eISSN: 1756-8722DOI: 10.1186/s13045-020-00978-zTitel-ID: cdi_doaj_primary_oai_doaj_org_article_798f2641d2d84fc38d531bd96beebc49
- Format
- –
- Schlagworte
- Androgen Receptor Antagonists - pharmacology, Androgen Receptor Antagonists - therapeutic use, Androgen receptor inhibitors (ARIs), Androgens, Anemia, Animals, Antimitotic agents, Antineoplastic agents, Antineoplastic Agents - pharmacology, Antineoplastic Agents - therapeutic use, Cabazitaxel, Cancer, Cancer metastasis, Cancer therapies, Cancer treatment, Care and treatment, Castration, Castration-resistant prostate cancer, Chemotherapy, Clinical outcomes, Clinical trials, Clinical Trials as Topic, Deoxyribonucleic acid, Development and progression, Dipeptides - pharmacology, Dipeptides - therapeutic use, DNA, DNA damage, DNA repair, Drug development, FDA approval, Genes, Genetic aspects, Health aspects, Heterocyclic Compounds, 1-Ring - pharmacology, Heterocyclic Compounds, 1-Ring - therapeutic use, Humans, Immunotherapy, Lutetium - pharmacology, Lutetium - therapeutic use, Male, Medical prognosis, Metastases, Metastasis, Metastatic prostate cancer, Monosaccharides, Mutation, Neoplasm Metastasis - drug therapy, Neoplasm Metastasis - pathology, Olaparib, Poly(ADP-ribose) polymerase, Poly(ADP-ribose) Polymerase Inhibitors - pharmacology, Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use, Polyadenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitor, Prostate cancer, Prostate-Specific Antigen, Prostate-specific membrane antigen (PSMA), Prostatic Neoplasms, Castration-Resistant - drug therapy, Prostatic Neoplasms, Castration-Resistant - pathology, Radioisotopes - pharmacology, Radioisotopes - therapeutic use, Rare earth metal compounds, Review, Ribose, Sugars